Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Zachary Prensky retiring from LBRX Board, not standing for reelection at 2026 Annual Meeting; no disagreement with company operations or policies.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Zachary Prensky retiring from LBRX Board, not standing for reelection at 2026 Annual Meeting; no disagreement with company operations or policies
- Prensky transitions to consulting role post-departure under amended Transition Agreement (originally dated Nov 26, 2024), effective June 3, 2026
- Unvested stock options continue vesting through duration of consulting agreement: extends equity alignment beyond board tenure
- Full terms of Transition Agreement Amendment deferred to 10-K filing for fiscal year ended Dec 31, 2025; no financial details currently disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.